Today: 14 July 2026
FIGS stock in focus: shares steady after Friday surge, tariffs and 2026 outlook back in play
2 March 2026
1 min read

FIGS stock in focus: shares steady after Friday surge, tariffs and 2026 outlook back in play

New York, March 2, 2026, 07:54 EST — Premarket

  • FIGS shares jumped 23.9% by Friday’s close, sticking close to $15.40 after hours.
  • The company pointed to tariff headwinds and projected revenue growth between 10% and 12% for 2026.
  • Management’s March 4 conference slot is on investor radar, with hopes pinned on new details.

FIGS Inc held steady in after-hours moves, giving back only a few cents following Friday’s surge. Investors now have an eye on tariffs and those 2026 targets again. Friday’s session wrapped with the stock at $15.45; after the close, it hovered near $15.40, public quotes showed.

FIGS has been under pressure to show it can return to growth following what its executives described as a post-pandemic “overhang” in demand for scrubs and related gear. The stock’s sharp gain Friday upended expectations in a hurry, and now the company faces a higher bar for performance in the quarters ahead.

Investors are left untangling how much of the rebound boils down to company moves—products, inventory, pricing—and how much just reflects a calmer setting following a rocky period for consumer stocks.

FIGS reported late Thursday that net revenues for the fourth quarter jumped 33% to $201.9 million. Net income also moved higher, reaching $18.5 million, or $0.10 per diluted share. Gross margin, though, fell to 62.9%, a drop of 440 basis points (4.4 percentage points), as the impact from increased tariffs and a $5.6 million inventory write-off hit results, according to the company. Chief executive Trina Spear described the quarter as a “remarkable 2025,” highlighting solid performance across the business. ir.wearfigs.com

During the earnings call, the company projected fiscal 2026 net revenue growth of 10% to 12% year-on-year, building its guidance around a 15% “global tariff.” By the end of 2025, it held $300.8 million in net cash, cash equivalents, and short-term investments, with $52 million still authorized for share buybacks. CEO Spear called the uniform market “replenishment-driven” and “non-cyclical.” CFO Sarah Oughtred, for her part, said the tariff landscape remains “fluid.”

Monday brings a test: will FIGS keep Friday’s gains when the bell rings? Investors are watching to see if the new premium sticks, with bets riding on steady demand as the company tweaks pricing and promotions.

But there’s a hitch. Tariffs aren’t standing still, and the company has already flagged that they’re starting to bite. Should costs outpace projections, or if customers balk at higher prices, margins could unravel fast. That’s particularly true after the recent rally, which has dragged in a wave of short-term cash.

Investors are eyeing management’s upcoming fireside chat at the Raymond James 47th Annual Institutional Investors Conference on March 4, looking for more details around demand, pricing, and tariffs.

After this, eyes shift to the next earnings report for FIGS. Market calendars, including a few tracked by traders, peg May 7 as the likely date, but so far the company hasn’t confirmed it in their own press releases.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

Stock Market Today

  • Astena Holdings (TSE:8095) lifts Q2 profit but 5-year slide keeps stock lagging
    July 14, 2026, 4:56 PM EDT. Astena Holdings (TSE:8095) reported Q2 2026 revenue at ¥18.0 billion and EPS of ¥20.56, both up from a year ago. Net income for the trailing 12 months swung to ¥2,316 million, with EPS at ¥57.37, reversing earlier annual losses. Still, earnings have been falling 17.7% each year over the past five years, which weighs on the outlook. Shares are trading at 9 times trailing earnings, well under the JP Pharmaceuticals sector average of 16.4. Discounted cash flow puts fair value at ¥437.74, below the ¥516 share price. Investors have mixed views as recent gains are offset by the longer-term profit decline.
Amazon stock in focus after $50 billion OpenAI partnership lands in SEC filing
Previous Story

Amazon stock in focus after $50 billion OpenAI partnership lands in SEC filing

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Next Story

Stock Market Today 03.03.2026

Go toTop